newsfilter
← Latest News
Business Wire·

Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera

TAKTYO:4502
  • Takeda received U.S. FDA approval for MIMRYLO (rusfertide), a first-in-class hepcidin mimetic, to treat erythrocytosis in adults with polycythemia vera (PV).
  • MIMRYLO regulates iron distribution to control hematocrit levels below 45%, the primary treatment goal for PV to prevent thrombotic events.
  • Approval was supported by Phase 3 VERIFY trial data showing 76.9% of patients achieved clinical response during Weeks 20-32.
  • Clinical results demonstrated MIMRYLO maintained hematocrit control, reduced the burden of phlebotomy, and improved fatigue scores.
  • The study included 293 PV patients who received MIMRYLO plus current standard of care versus placebo plus standard of care.
  • Common adverse reactions (>15%) included injection site reactions (56%) and anemia (16%).
  • Warnings include potential new or worsening thrombocytosis, injection site reactions, and embryo-fetal toxicity requiring contraception.
  • MIMRYLO is administered via once-weekly subcutaneous injection.
  • The VERIFY trial is currently in an open-label extension phase, with Takeda seeking regulatory approval outside the U.S.
  • This approval does not alter Takeda's consolidated financial forecast for the fiscal year ending March 31, 2027.
  • Protagonist originally discovered MIMRYLO before Takeda secured exclusive global development and commercialization rights.